Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1.

Peacock JW, Takeuchi A, Hayashi N, Liu L, Tam KJ, Al Nakouzi N, Khazamipour N, Tombe T, Dejima T, Lee KC, Shiota M, Thaper D, Lee WC, Hui DH, Kuruma H, Ivanova L, Yenki P, Jiao IZ, Khosravi S, Mui AL, Fazli L, Zoubeidi A, Daugaard M, Gleave ME, Ong CJ.

EMBO Mol Med. 2018 Feb;10(2):219-238. doi: 10.15252/emmm.201707689.

2.

Prospective comparison of the efficacy of caudal versus periprostatic nerve block, both with intrarectal local anesthesia, during transrectal ultrasonography-guided prostatic needle biopsy.

Urabe F, Kimura T, Shimomura T, Onuma H, Yamamoto T, Sasaki H, Miki J, Kuruma H, Miki K, Egawa S.

Scand J Urol. 2017 Aug;51(4):245-250. doi: 10.1080/21681805.2017.1318299. Epub 2017 Apr 26.

PMID:
28443752
3.

[EXPRESSION OF PLAKIN FAMILY IN UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT].

Hasegawa Y, Kamata Y, Yorozu T, Takahashi H, Kimura T, Kuruma H, Tabata R, Shimomura T, Yamada H, Sasaki H, Egawa S.

Nihon Hinyokika Gakkai Zasshi. 2017;108(2):87-95. doi: 10.5980/jpnjurol.108.87. Japanese.

4.

The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.

Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KM, Angeles A, Johnson F, Wyatt AW, Fazli L, Gleave ME, Lin D, Rubin MA, Collins CC, Wang Y, Beltran H, Zoubeidi A.

Cancer Discov. 2017 Jan;7(1):54-71. doi: 10.1158/2159-8290.CD-15-1263. Epub 2016 Oct 26.

5.

Do androgen deprivation and the biologically equivalent dose matter in low-dose-rate brachytherapy for intermediate-risk prostate cancer?

Tabata R, Kimura T, Kuruma H, Sasaki H, Kido M, Miki K, Takahashi H, Aoki M, Egawa S.

Cancer Med. 2016 Sep;5(9):2314-22. doi: 10.1002/cam4.820. Epub 2016 Jul 25.

6.

Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7.

Shiota M, Fujimoto N, Imada K, Yokomizo A, Itsumi M, Takeuchi A, Kuruma H, Inokuchi J, Tatsugami K, Uchiumi T, Oda Y, Naito S.

J Natl Cancer Inst. 2016 Feb 8;108(7). doi: 10.1093/jnci/djw005. Print 2016 Jul.

PMID:
26857528
7.

Time Trends in Histological Features of Latent Prostate Cancer in Japan.

Kimura T, Takahashi H, Okayasu M, Kido M, Inaba H, Kuruma H, Yamamoto T, Furusato B, Furusato M, Wada T, Egawa S.

J Urol. 2016 May;195(5):1415-1420. doi: 10.1016/j.juro.2015.11.068. Epub 2015 Dec 8.

PMID:
26678955
8.

Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.

Shiota M, Itsumi M, Takeuchi A, Imada K, Yokomizo A, Kuruma H, Inokuchi J, Tatsugami K, Uchiumi T, Oda Y, Naito S.

Endocr Relat Cancer. 2015 Dec;22(6):889-900. doi: 10.1530/ERC-15-0225. Epub 2015 Aug 26.

PMID:
26311513
9.

Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.

Shiota M, Bishop JL, Takeuchi A, Nip KM, Cordonnier T, Beraldi E, Kuruma H, Gleave ME, Zoubeidi A.

Oncotarget. 2015 Apr 20;6(11):9086-98.

10.

Loss of periplakin expression is associated with pathological stage and cancer-specific survival in patients with urothelial carcinoma of the urinary bladder.

Matsumoto K, Ikeda M, Sato Y, Kuruma H, Kamata Y, Nishimori T, Tomonaga T, Nomura F, Egawa S, Iwamura M.

Biomed Res. 2014;35(3):201-6.

11.

Pulmonary metastases after low-dose-rate brachytherapy for localized prostate cancer.

Kido M, Kuruma H, Sasaki H, Miki K, Aoki M, Kimura T, Takahash H, Kanehira C, Egawa S.

Korean J Urol. 2014 May;55(5):309-14. doi: 10.4111/kju.2014.55.5.309. Epub 2014 May 12.

12.

Salvage partial brachytherapy for prostate cancer recurrence after primary brachytherapy.

Sasaki H, Kido M, Miki K, Kuruma H, Takahashi H, Aoki M, Egawa S.

Int J Urol. 2014 Jun;21(6):572-7. doi: 10.1111/iju.12373. Epub 2013 Dec 23.

13.

Mid-term outcome of permanent prostate iodine-125 brachytherapy in Japanese patients.

Kimura T, Kido M, Miki K, Yamamoto T, Sasaki H, Kuruma H, Hayashi N, Takahashi H, Aoki M, Egawa S.

Int J Urol. 2014 May;21(5):473-8. doi: 10.1111/iju.12347. Epub 2013 Nov 20.

14.

Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability.

Matsumoto H, Yamamoto Y, Shiota M, Kuruma H, Beraldi E, Matsuyama H, Zoubeidi A, Gleave M.

Cancer Res. 2013 Aug 15;73(16):5206-17. doi: 10.1158/0008-5472.CAN-13-0359. Epub 2013 Jun 20.

15.

Castration-resistant prostate cancer: novel therapeutics pre- or post- taxane administration.

Shiota M, Yokomizo A, Fujimoto N, Kuruma H, Naito S.

Curr Cancer Drug Targets. 2013 May;13(4):444-59. Review.

PMID:
23517595
16.

A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.

Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, Briere D, Los G, Gleave M, Fanjul A, Zoubeidi A.

Mol Cancer Ther. 2013 May;12(5):567-76. doi: 10.1158/1535-7163.MCT-12-0798. Epub 2013 Mar 14.

17.

Words of Wisdom: re: international variation in prostate cancer incidence and mortality rates.

Kuruma H, Egawa S.

Eur Urol. 2013 Mar;63(3):583-4. doi: 10.1016/j.eururo.2012.12.012. No abstract available.

PMID:
23357896
18.

[Solitary adrenal metastasis of bladder carcinoma : a case report].

Honda M, Suzuki K, Sugaya S, Kuruma H, Abe M, Koshitaka Y, Hasegawa Y, Kondo N, Egawa S.

Hinyokika Kiyo. 2012 Sep;58(9):495-7. Japanese.

19.

[New biomarkers for the prostate cancer].

Ishii G, Kimura T, Kuruma H, Egawa S.

Nihon Rinsho. 2012 May;70(5):828-32. Review. Japanese.

PMID:
22620008
20.

[New marker proteins for prostate cancer].

Hayashi N, Kuruma H, Egawa S.

Nihon Rinsho. 2011 Jun;69 Suppl 5:140-4. Review. Japanese. No abstract available.

PMID:
22207959

Supplemental Content

Loading ...
Support Center